Research findings: In conjunction with researchers at Roche and the National Taiwan University Hospital and College of Medicine in Taipei, the conclusions of the study demonstrated that LungFlag™ was able to work on Taiwanese EMR data and presented superiority over criteria based selection of individuals (USPSTF) and performed better than gold standard benchmark risk model PLCOm2012 that was adapted to be used on EMR data. The results were comparable to the previous validation studies and indicates that LungFlag™ can immediately support Taiwan screening program in identifying elevated risk populations among ever-smokers and potentially also on never-smokers populations.

Allelica has created a secure and trusted platform for Polygenic Risk Score analysis and reporting to equip health systems and clinical laboratories with cutting-edge tools to reduce the impact of common disease through genomic medicine. 

All processes performed on the Allelica platform are fully HIPAA and GDPR-compliant. ISO 13485 and ISO 9001 certifications guarantee that Allelica applies medical device quality management processes every step of the way.

Allelica is working with leading health systems and genetics laboratories in the United States and across Europe to advance disease prevention through widened application of PRS in healthcare.